As gene therapy developers progress through the clinical phases to commercial manufacture, additional capacity may be required resulting in the need to move to a new facility or invest in a build program. The DPS team has been designing these advanced facilities since the first gene therapy revolution in the late 1990s and brings many years of experience in the successful delivery of clinical and commercial facilities for our clients.
We understand our clients' challenges in viral vector production and the evolving platforms for these highly complex molecules. We understand the challenges in building robust processes under tight schedules.
Let us share the best current strategies in flexible facilities, addressing rapid deployment needs while navigating the regulatory pathway to facility licensure. Contact us now to discuss your next gene therapy project.
DPS provided detailed design services to assist Brammer in developing a new cGMP manufacturing and QC operations facility.
Having successfully completed several gene therapy projects, Brammer Bio hired DPS to work on the renovation and expansion of its GMP facility.
CSL plan to build a Multi-Purpose Biologics Facility (MFP) to support their manufacturing strategy; particularly to develop and support growth in gene and cell therapy.
To support its rapid transition into clinical development, the client is planning to build a new cGMP Manufacturing/ Pilot and QC Operations facility.
DPS Group developed a concept design for a large scale EMEA viral vector production facility in Sassenheim, the Netherlands.
DPS was hired to provide engineering and design services for a new cGMP manufacturing facility having completed the process definition and test fit phases.
DPS was commissioned to carry out a concept design study for a new Multimodal Production & Development Facility in Song-do, Incheon, South Korea for the manufacture of multi-platform viral vectors, plasmid DNA and monoclonal antibodies.
Sarepta, a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, hired DPS to work on numerous projects at both its Massachusetts and Ohio facilities.
DPS was engaged to assist Vertex in determining feasibility to build a multi-product, flexible Gene / Cell Therapy Manufacturing facility in Massachusetts.